ArticleInternational journal of physiology, pathophysiology and pharmacology2025
Bupivacaine with methylprednisolone in ESP block reduces postoperative pain and opioid consumption after lumbar spine surgery.
Article in International journal of physiology, pathophysiology and pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative pain management in spine surgery is challenging. While opioids are effective, their significant adverse effects, including respiratory depression, necessitate opioid-sparing strategies. The Erector Spinae Plane (ESP) block has emerged as a promising regional technique. This study investigates whether the addition of methylprednisolone to bupivacaine in an ESP block enhances postoperative analgesia and reduces opioid consumption in patients undergoing lumbar spine surgery.
methodThis prospective, randomized clinical trial (Ethical Approval ID: IR.SBMU.RETECH.REC.1403.467) included 64 patients (18-65 years) for two- or three-level lumbar spine surgery. Patients were randomized into two groups: the control group (bupivacaine alone) and the intervention group (bupivacaine combined with methylprednisolone). Data were collected on intraoperative metrics (e.g., fluid therapy, blood loss, operation time), opioid consumption, postoperative pain scores (NRS), incidence of nausea and shivering, blood glucose levels, and need for rescue analgesia up to one month post-surgery.
resultsThe methylprednisolone group showed significantly lower narcotics consumption (intraoperatively and in the PACU). The pain level (NRS) was also lower in this group for up to four weeks post-operation. There were no significant inter-group differences in surgery duration, anesthetic consumption, bleeding, or the incidence of nausea and chills.
conclusionThe use of methylprednisolone as an adjuvant to bupivacaine in the ESP block improves the quality and duration of analgesia in spine surgery patients. However, the transient elevation in blood glucose levels highlights the need for careful glucose monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.